Recent news on Fuzeon

MicroMass Names ECD  -  May 24, 2007
Adweek,Cobb's pharmaceutical brand experience includes Alimta, Cymbalta, Fuzeon and Xigris. Cobb will manage MircoMass' 30-person creative group and serve as a

Zacks Bull and Bear of the Day Highlights: FormFactor, Solectron ...  -  May 17, 2007
Business Wire (press release),The most significant outcome of this anti-viral fusion technology is the development of Fuzeon for the treatment of HIV. Fuzeon sales have been relatively

New Rx may wipe out HIV - top doc  -  May 16, 2007
New York Daily News,The medications - Roche's Fuzeon and Merck's Isentress, which is still in development - could make HIV disappear in patients who have already limited the

SmallCapReview.com Introduces Sirenza Microdevices, JAKKS Pacific ...  -  May 7, 2007
PR Leap (press release),FUZEON, approved in the US, Canada and European Union, is the first in a new class of anti-HIV drugs called fusion inhibitors. Trimeris is developing FUZEON

Behavioral Insights Prove to Be a Draw Not Only For Brands, But ...  -  May 22, 2007
Business Wire (press release),Cobb’s pharmaceutical brand experience includes Gemzar, Alimta, Humalog, Fuzeon, Cymbalta and Xigris. “Jamie is a proven creative leader and change agent,�

Pediatric HIV/AIDS research funds cut  -  May 21, 2007
Inside Bay Area,One 13-year-old girl didn't respond to any of the approved drugs and now takes Fuzeon, manufactured by Roche Pharmaceuticals, which must be injected twice a

Top US Scientist to Use New AIDS Drugs Seeking Cure (Update2)  -  May 15, 2007
BloombergTreatment in the next group of patients will probably include Roche's Fuzeon, which prevents the virus from attaching to immune cells, and Merck's Isentress

Trimeris Up on Better Fuzeon Sales  -  Apr 18, 2007
Forbes,Trimeris Inc. shares surged Wednesday after the biopharmaceutical company said sales of its HIV drug Fuzeon rose 16 percent in the first quarter,

Trimeris Up on Better Fuzeon Sales  -  Apr 18, 2007
Forbes,Trimeris Inc. shares surged Wednesday after the biopharmaceutical company said sales of its HIV drug Fuzeon rose 16 percent for the quarter, but analysts

Trimeris Reports First Quarter 2007 Fuzeon Sales Results  -  Apr 18, 2007
PharmaLive.com (press release),Net sales of FUZEON in the US and Canada for the first quarter of 2007 were $29.3 million, up 7 percent from $27.4 million in the first quarter of 2006.

Trimeris Reports Boost in Fuzeon Sales, Especially Outside US  -  Apr 19, 2007
Local Tech Wire,Morrisville — Sales of the HIV drug Fuzeon surged 16 percent in the first quarter, with foreign business driving the increase, pharmaceutical firm Trimeris

Trimeris Reports First Quarter 2007 FUZEON(R) Sales Results  -  Apr 17, 2007
Genetic Engineering News (press release),Trimeris, Inc. (NASDAQ: TRMS) today announced worldwide net sales of FUZEON for the first quarter of 2007 were $64.3 million, an increase of 16 percent from

Trimeris says Q1 sales of HIV drug Fuzeon up 16 pct  -  Apr 17, 2007
ReutersIn a statement, the company said worldwide net sales of Fuzeon were $64.3 million in the latest quarter, compared with $55.4 million in the year-ago quarter

Trimeris Isn't Tumbling  -  Apr 23, 2007
Motley FoolTrimeris splits the profits on all revenue from Fuzeon in the US and Canada with Roche, and receives royalties on sales of the drug in the rest of the world

Trimeris plans more layoffs, shifts Fuzeon responsibilities  -  Apr 3, 2007
Milwaukee Business Journal,Trimeris developed Fuzeon in collaboration with Roche. Earlier this year, Trimeris announced that it had bought back the rights from Roche to develop new

Sales of Trimeris' HIV drug up 16% in 1Q  -  Apr 18, 2007
Bizjournals.com,Trimeris Inc. said Tuesday that its HIV drug Fuzeon generated a 16 percent increase in worldwide sales in the 2007 first quarter.

Market Report -- In Play (TRMS)  -  Apr 17, 2007
MSN MoneyTrimeris announces worlwide net sales of Fuzeon for Q1 were $64.3 mln Co announces worldwide net sales of Fuzeon for the first qtr of 2007 were $64.3 mln,

Sales of Trimeris' AIDS drug slow  -  Apr 18, 2007
News & Observer,DURHAM - Trimeris, the troubled Durham company that markets the AIDS treatment Fuzeon with its Swiss partner Roche, reported that worldwide sales increases

Trimeris HIV Drug Sales Grow 16 Percent  -  Apr 17, 2007
Forbes,Biopharmaceutical company Trimeris Inc. said sales of its HIV drug Fuzeon increased 16 percent in the first quarter, driven by growth outside the US

Trimeris HIV Drug Sales Grow 16 Percent  -  Apr 17, 2007
Houston Chronicle,MORRISVILLE, NC — Biopharmaceutical company Trimeris Inc. said sales of its HIV drug Fuzeon increased 16 percent in the first quarter, driven by growth

Piper Jaffray Comments on Trimeris (TRMS)  -  Apr 10, 2007
StreetInsider.com (subscription),The trial will enroll approximately 170 patients with undetectable HIV levels treated with Fuzeon who will be randomized to either maintain their Fuzeon

Changing of the guard in HIV treatment  -  Apr 12, 2007
Pharmaceutical Business ReviewHowever, Fuzeon's cumbersome administration - it has to be injected twice daily and frequently causes side effects such as injection site reactions - has

Analysis: HIV market to top $10 billion  -  Apr 11, 2007
United Press InternationalCelsentri and Isentress are expected to steal market share from Roche's Fuzeon, which currently dominates the late-stage therapy.

Trimeris Plans Further Layoffs  -  Apr 2, 2007
Local Tech Wire,An undisclosed number of workers and a “number of the Company’s responsibilities� for the HIV drug Fuzeon would be transferred to Roche, Trimeris said.

Durham biotech puts former Trimeris president at helm  -  Apr 10, 2007
Bizjournals.com,Ellis served as president of publicly traded Durham pharmaceutical company Trimeris (Nasdaq: TRMS), where he helped develop HIV treatment Fuzeon.

Phase Bioscience appoints top guy  -  Apr 10, 2007
Durham Herald Sun,Ellis was most recently president of Trimeris, the Morrisville firm that developed the HIV treatment Fuzeon. Prior to that Ellis was a co-founder of

Africa: Daily HIV/Aids Report  -  Apr 21, 2007
AllAfrica.com,He added that the peptide might work synergistically with the antiretroviral drug Fuzeon, which also is known as enfuvirtide or T-20 and was approved by FDA

German researchers find protein that blocks HIV  -  Apr 20, 2007
San Francisco Chronicle,Greene said the peptide might work synergistically with Fuzeon, commonly called T-20, an injectable drug approved in 2003 and used by AIDS patients who have

Scientists discover human substance that fights AIDS virus  -  Apr 19, 2007
Raw Story,It gained European certification in 2003 under the name Fuzeon. The Ulm team said virip attacks gp41 at a different place.

Survey: Medicare Part D failing PWAs  -  Apr 19, 2007
Bay Area Reporter,It allowed "prior authorization," approval of a doctor's prescription by the insurance provider before it can be filled, only for Fuzeon, the most expensive

Wednesday's Small-Cap Winners & Losers  -  Apr 18, 2007
TheStreet.comOn the flip side, biotech Trimeris (TRMS - Cramer's Take - Stockpickr) said its main product -- an HIV treatment called Fuzeon -- brought in around 16% more

Major Averages Mixed In The Middle Of Wednesday's Trading  -  Apr 18, 2007
Trading Markets,The drug maker saw its stock rise after it announced on Wednesday that sales for its drug Fuzeon were up 16%. By the middle of trading, Trimeris was up 15%,

StreetInsider.com Pre-Open Movers 04/18  -  Apr 18, 2007
StreetInsider.com (subscription),Trimeris, Inc. (NASDAQ: TRMS) 3.6% LOWER; announced worldwide net sales of FUZEON for the first quarter of 2007 were $64.3 million, an increase of 16

Roche Posts Strong First Quarter Sales – Upgrade of Core Earnings ...  -  Apr 18, 2007
PharmaLive.com (press release),Sales of the HIV medicine Fuzeon increased by 12%, and Invirase/Fortovase by 23%. CellCept sales rose by 7% and remained the top-selling branded

Medicare prescription drug benefit failing patients with HIV  -  Apr 12, 2007
Dallas Voice,It allowed “prior authorization� — approval of a doctor’s prescription by the insurance provider before it can be filled — only for Fuzeon,

NC’s Phase BioScience appoints former Trimeris exec as new CEO  -  Apr 10, 2007
TechJournal South,Most recently Dr. Ellis was President of Trimeris, Inc. where he was instrumental in the development of FUZEON, the first injectable peptide approved for

Phase Bioscience, Inc. appoints Nick Ellis as President and CEO ...  -  Apr 10, 2007
Carolina Newswire (press release),Most recently, Dr. Ellis was President of Trimeris, Inc. where he was instrumental in the development of FUZEON, the first injectable peptide approved for

Phase Bioscience Replaces CEO with Former Trimeris President  -  Apr 10, 2007
WRAL.com,Ellis helped develop the HIV drug Fuzeon while working at Trimeris. He also worked at Burroughs Wellcome where he was involved in virology research.

Biotech In Review: Bidding War Erupts For Biosite  -  Apr 7, 2007
Seeking Alpha,Trimeris (TRMS) will further cut its workforce, as Roche (RHHBY) takes over marketing responsibility for Fuzeon, an HIV treatment whose sales have been

Survey Finds Medicare Part D Failing People with HIV/AIDS  -  Apr 6, 2007
Kansas City infoZine,...the Centers for Medicare and Medicaid Services (CMS) specifically exempts all but one antiretroviral, enfuvirtide (Fuzeon), from prior authorization.

Darunavir looking promising as companion for agents in new HIV ...  -  Apr 4, 2007
Aidsmap,In the POWER 1 & 2 studies individuals who had no prior exposure to the fusion inhibitor enfuvirtide (Fuzeon), and who included the drug in their optimised

NATIONAL NEWS National News  -  Mar 30, 2007
New York Blade,If approved, Raltegravir and Merck, both oral, would be the first new drugs to represent a new “class� of anti-HIV drugs since 2003, when Fuzeon was

HIV - Results With New Integrase Inhibitor Plus FUZEON And Boosted ...  -  Mar 6, 2007
Medical News Today (press release),Virtually all patients (98 percent) who received the investigational integrase inhibitor raltegravir, along with FUZEON ® (enfuvirtide) and an active

Results with New Integrase Inhibitor Plus FUZEON and Boosted ...  -  Mar 2, 2007
dBusinessNews Newark (press release),Because FUZEON and/or darunavir/r were included in a patient’s background regimen only at the judgement of the investigator after consideration of

Trimeris HIV Drug Fuzeon Shows Promise in New Combination Treatment  -  Mar 3, 2007
Local Tech Wire,MORRISVILLE, NC – The HIV drug Fuzeon developed by Trimeris shows promise in treating patients who have developed resistance to treatment, according to

Trimeris executives were asked to retire  -  Mar 22, 2007
Durham Herald Sun,The company's lone product, Fuzeon, hit the US and European markets in 2003. When it was approved by federal regulators, the drug was described as a unique

Results with New Integrase Inhibitor Plus FUZEON (TRMS) and ...  -  Mar 1, 2007
StreetInsider.com (subscription),FUZEON, co-developed by Roche and Trimeris (Nasdaq: TRMS), is the first and only fusion inhibitor available for the treatment of HIV.

Trimeris Gets Trimmed  -  Mar 19, 2007
Motley FoolAs was announced in February, marketing partner Roche's sales of Fuzeon were $249 million last year with a current run-rate of over $290 million.

Upheaval and Change at Trimeris Can’t Erase Memories of ...  -  Mar 19, 2007
Local Tech Wire,...“It’sa feeling that is indescribable because of what the patients are up against and their response to Fuzeon,� said Bolognesi. “We now have a large number

Shares drop almost a third  -  Mar 17, 2007
News & Observer,Trimeris has struggled after lackluster sales of its AIDS treatment Fuzeon disappointed high expectations among investors three years ago.

AIDS Pioneer Dani Bolognesi Retires in Management Shakeup at Trimeris  -  Mar 15, 2007
WRAL.com,While the two companies will continue to partner on sales, marketing and production of Fuzeon, Roche is returning one potential drug product and other

Trimeris Reports Financial Results for the Fourth Quarter and Year ...  -  Mar 16, 2007
PharmaLive.com (press release),This increase was primarily influenced by strong global sales of FUZEON which reached $73.3 million, a growth of 16 percent over the same period last year.

Trimeris replacing two top execs  -  Mar 16, 2007
News & Observer,Trimeris reported its first profitable year on strong sales of its AIDS drug Fuzeon. But the restructuring put into question whether the company can remain

Trimeris and Roche Amend Research Agreement Covering Next ...  -  Mar 16, 2007
PipelineReview.com (press release),FUZEON, approved in the US, Canada and European Union, is the first in a new class of anti-HIV drugs called fusion inhibitors. Trimeris is developing FUZEON

Trimeris stock plunges on CEO's departure  -  Mar 17, 2007
Bizjournals.com,Thursday's announcement came on the heels of a difficult year for Trimeris, whose HIV drug Fuzeon has failed to reach expectations. The company announced in

Trimeris reports profit, management shake-up  -  Mar 15, 2007
News & Observer,Strong sales of its AIDS drug Fuzeon helped Trimeris record its first profitable year in 2006, the company reported this afternoon.

Trimeris forced out CEO/founder and CFO  -  Mar 21, 2007
TechJournal South,...the company announced the two executives were departing and the company was ending its partnership with Roche, which has marketed its AIDS drug, Fuzeon.

Trimeris Shares Steady in Monday Trading  -  Mar 20, 2007
Local Tech Wire,Trimeris sells in conjunction with Roche an AIDS drug called Fuzeon, and Trimeris did for the first time report a profitable year on Thursday in its annual

Trimeris reports $4.7M 4Q profit  -  Mar 19, 2007
Durham Herald Sun,Trimeris divides the costs and revenue from US and Canadian sales of Fuzeon evenly with its partner Roche and receives about 9 percent royalty for sales in

Troubling Times for Trimeris  -  Mar 16, 2007
TheStreet.comTrimeris' sole source of revenue is Fuzeon, an HIV drug that has struggled commercially because it must be given by a painful injection and it has a host of

Trimeris, Roche amend research pact  -  Mar 15, 2007
MarketWatchThe commercial arrangement between Roche and Trimeris governing Fuzeon sales remains unchanged. Trimeris has the sole right to continue development of

Trimeris Announces Retirement Of Dani Bolognesi, CEO And Chief ...  -  Mar 15, 2007
Trading Markets,The commercial arrangement between Roche and Trimeris governing FUZEON sales remains unchanged. TRMS closed Thursday's trading at $10.07, up $0.06 or 0.60%

Trimeris (TRMS) Tops Q4 Earnings, Amends Research Agreement with ...  -  Mar 15, 2007
StreetInsider.com (subscription),The commercial arrangement between Roche and Trimeris governing FUZEON sales remains unchanged. Separately, TRMS announced that effective March 16, 2007,

Roche says combination therapy successful against HIV  -  Mar 2, 2007
Pharmaceutical Business ReviewRoche has said 98% of patients who received the investigational integrase inhibitor raltegravir, along with Fuzeon and the protease inhibitor Prezista,

Two new medicines funded for people with HIV  -  Mar 14, 2007
Scoop.co.nz,In recent months, PHARMAC has approved funding for Kivexa (a combination treatment) Fuzeon (the first fusion inhibitor, a new class of anti-HIV drug) and

Ahead of the Bell: Trimeris Falls  -  Mar 16, 2007
Forbes,Morgan Stanley (nyse: MS - news - people ) analyst Steven Harr said Fuzeon, an HIV drug developed by Trimeris that Roche is marketing, will face stronger

Ahead of the Bell: Trimeris Falls  -  Mar 16, 2007
Houston Chronicle,Morgan Stanley analyst Steven Harr said Fuzeon, an HIV drug developed by Trimeris that Roche is marketing, will face stronger competition and may have an

Ahead of the Bell: Trimeris Falls  -  Mar 16, 2007
Forbes,Merrill Lynch (nyse: MER - news - people ) analyst Steven Harr said Fuzeon, an HIV drug developed by Trimeris that Roche is marketing, will face stronger

Ahead of the Bell: Trimeris Falls  -  Mar 16, 2007
Houston Chronicle,Merrill Lynch analyst Steven Harr said Fuzeon, an HIV drug developed by Trimeris that Roche is marketing, will face stronger competition and may have an

Top executives leave RTP's Trimeris, stock collapses  -  Mar 16, 2007
TechJournal South,The company had previously announced plans to reduce its workforce by up to 25% in December as its HIV drug Fuzeon has not met expectations.

Trimeris shares drop in morning trading  -  Mar 16, 2007
News & Observer,Trimeris has struggled since lackluster sales of its AIDS treatment Fuzeon disappointed high expectations three years ago.

Trimeris "hold," estimates raised  -  Mar 16, 2007
newratings.comTrimeris has reiterated its belief that the worldwide Fuzeon sales in 2007 are likely to generate modest y/y growth. Trimeris’ future profitability mainly

Trimeris, Roche Amend Deals  -  Mar 15, 2007
Houston Chronicle,...licensed to the company in 1999, with the exception that Roche retains an exclusive license to manufacture and sell the HIV drug Fuzeon worldwide.

New AIDS treatments on horizon  -  Mar 8, 2007
Dallas Voice,It acts at the same point in the virus’ life cycle as Fuzeon (T-20), but with a somewhat different mechanism of action. And unlike Fuzeon, which must be

New era of HIV treatment on the horizon  -  Mar 8, 2007
Bay Area Reporter,Fuzeon (T-20) acts at the same point in the virus' lifecycle but with a somewhat different mechanism of action. And, unlike Fuzeon, which must be injected

New AIDS Medications Moving Nearer to the Market  -  Feb 28, 2007
6abc.com,The two new drugs would represent the first new classes since 2003, when an injectable drug called Fuzeon was approved. They would be the first new classes

Biotech Day in Review: Hopeful Results from HIV Conference  -  Mar 4, 2007
Seeking Alpha,Roche (RHHBY) and Trimeris (TRMS) said that Fuzeon produced an undetectable level of HIV in 98% of the recipients. Fuzeon was given along with Merck’s

CROI 2007: A great leap forward  -  Mar 21, 2007
NAPWA,Among those whose background regimen included T-20 (enfuvirtide/Fuzeon) and darunavir (TMC-114/Prezista), 98 percent of patients achieved viral load below

Trimeris CEO To Receive Cash, Stock in Severance Package  -  Mar 21, 2007
WRAL.com,Bolognesi has been a pioneer in AIDS research and helped create the HIV drug Fuzeon, which Trimeris markets and sells internationally in partnership with

The angel of AIDS patients  -  Mar 19, 2007
Greater Milwaukee Today,Given her long experience in the field, Busalacchi frequently helps run clinical trials for new drugs with tongue-tripping names like Saquinavir, Fuzeon and

Biotech In Review: Adams Respiratory Guides Lower  -  Mar 18, 2007
Seeking Alpha,Roche also returned other assets from a 1999 partnership, although it kept its rights to distribute Fuzeon. Trimeris gained 30%, climbing $2.95 to $7.12.

Trimeris Q4 EPS Rises; Revenues Up 57%; Reiterates FY07 Net Sales ...  -  Mar 16, 2007
Trading Markets,Looking ahead, Trimeris reiterated its previous outlook that total worldwide net sales of FUZEON will show modest top-line growth in 2007 compared to 2006.

This site is for informational purposes only--it does not offer medical advice or sell health products. If you need assistance, contact your physician or healthcare professional